6533b85dfe1ef96bd12bf144

RESEARCH PRODUCT

false

subject

0301 basic medicine030204 cardiovascular system & hematologyCatalysisInorganic Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineP2Y12PhosphatidylcholineLipidomicsmedicinePlateletPhysical and Theoretical ChemistryLipid bilayerMolecular BiologySpectroscopyActive metaboliteOrganic ChemistryGeneral MedicineComputer Science Applications030104 developmental biologyMembraneBiochemistrychemistrylipids (amino acids peptides and proteins)Ticagrelormedicine.drug

description

Lipids contained in the plasma membrane of platelets play an important role in platelet function. Modifications in the lipid composition can fluidify or rigidify the environment around embedded receptors, in order to facilitate the access of the receptor by the drug. However, data concerning the lipid composition of platelet plasma membrane need to be updated. In addition, data on the impact of drugs on plasma membrane composition, in particular antiplatelet agents, remain sparse. After isolation of platelet plasma membrane, we assessed, using lipidomics, the effect of ticagrelor, a P2Y12 antagonist, and its active metabolite on the lipid composition of these plasma membranes. We describe the exact lipid composition of plasma membrane, including all sub-species. Ticagrelor and its active metabolite significantly increased cholesterol and phosphatidylcholine ether with short saturated acyl chains 16:0/16:0, and decreased phosphatidylcholine, suggesting overall rigidification of the membrane. Furthermore, ticagrelor and its active metabolite decreased some arachidonylated plasmalogens, suggesting a decrease in availability of arachidonic acid from the membrane phospholipids for synthesis of biologically active mediators. To conclude, ticagrelor and its active metabolite seem to influence the lipid environment of receptors embedded in the lipid bilayer and modify the behavior of the plasma membrane.